TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Adherence to Medication
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Reduction of sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tooth color evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gender division of caregiving/domestic tasks
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Men's participation in family planning and maternal, newborn and child health
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Gender-related attitudes
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Women's experiences of intimate partner violence
Endpoint domain: Adverse events/effects
Primary endpoint: Change in endocrine levels post treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Complete Response Rate (CR+CRu)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in hamstring muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: changes in SARS (seasonal allergic rhinitis symptoms)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: changes in Mini RQLQ (mini rhinoconjunctivitis quality of life questionnaire)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: changes in specific IgE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Clinical healing of bile leakage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Self-reported condom/contraceptive use or no sex
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Self-reported use of any clinic services
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change From Baseline in Mean Intraocular Pressure (IOP) in the Study Eye to Month 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in the Number of Topical IOP-Lowering Medications in the Study Eyes to Month 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change From Baseline in IOP in the Study Eyes to Month 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in the Number of Topical IOP-Lowering Medications in the Study Eyes to Month 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiographic Progression-Free Survival (PFS)
Endpoint domain: Mortality/survival
Primary endpoint: Oral microbial signature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Removal rate of β2-microglobulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient experiences of the intervention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Success rate of PEG via introducer method
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pattern of AA metabolite excretion/secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Postoperative Pulmonary Embolism
Endpoint domain: Adverse events/effects
Primary endpoint: success rate of PLMA insertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proportion of patients experiencing clinical response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Fracture Healing (Union) at 12 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone In-growth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Probability of Event Free Survival (EFS)
Endpoint domain: Mortality/survival
Primary endpoint: Half-life (t-half)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in Premature Ventricular Beats
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pain Intensity
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Shuttle Walk Test Distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area of flare reaction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area of primary and secondary hyperalgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 30-Day Sustained Abstinence From Smoking
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Solicited local and general adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Serious Adverse events (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Adverse events (AE) of specific interest
Endpoint domain: Adverse events/effects
Primary endpoint: Haematological, biochemical or urinary laboratory abnormalities
Endpoint domain: Adverse events/effects
Primary endpoint: Static hyperinflation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: pain score (NRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain related to incision
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient tolerance as assessed by tracheostomy cannula comfort score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Allergen PC15 Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Inter- and intra-observer agreement for detection of abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percentage change of fractional synthetic rate (FSR) of Apo A-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage change of flow mediated dilatation (FMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Pain Severity Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dynamic Balance (mSEBT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dynamic Balance (Emery Test)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ankle stability (Side Hop Test)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HO-1 mRNA and protein expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mitochondria function of musculus vastus lateralis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stroke volume index (SVi) variation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Molecular Response at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful paired biopsies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Urinary L:M Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Vibration-induced muscle electrical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: changes in toxic reaction
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Time in Target Range (% of Sensor Glucose)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Non-suicidal self-injury symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Articular Cartilage Collagen Organization in the Overall Cartilage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change From Baseline of LNA043 to Placebo in Cartilage Volume in the Femoral Medial Index Region
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change From Baseline of LNA043 to Placebo in Cartilage Thickness in the Femoral Medial Index Region
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Atrial fibrillation symptoms severity
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of Incisional Hernia at Clinical examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Rate of Incisional Hernia at Ultrasound examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Any self-reported falls
Endpoint domain: Adverse events/effects
Primary endpoint: Healthcare utilization
Endpoint domain: Resource use
Primary endpoint: Gingival Bleeding index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Turesky Plaque Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of antigen-specific T memory phenotype cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: At Least 75% Reduction in Eczema Area and Severity Index (EASI75) at Week 16
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall response rate to PS-341 therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Baseline corrected AUCt of CKD-845
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Baseline corrected Cmax of CKD-845
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Patients With Clostridium Difficile Infection
Endpoint domain: Adverse events/effects
Primary endpoint: Performance during HFS
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Feasibility of protocol adherence
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: frequency and duration of symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time intervals between prediagnostic sentinel events
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: description of prediagnostic patient experiences
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Mean pain measured by Visual Analogue Scale (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with pain intensity decrease to less than 50% of baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lowering of blood pressure in mmHg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Bleeding Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: EQELS Change in Mobility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Changes in tumor antigen peptide specific immune responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Fat Attenuation Index (FAI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of participants with BCVA gain≥ 15 Letters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants with IOP ≥20 mm Hg
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle health
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change from baseline on the Social Responsiveness Scale-2 Total Score at 12 Weeks
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Mean change from baseline on the Brief Observation of Communication Change (BOSCC) total score at 12 Weeks
Endpoint domain: Life impact
Endpoint subdomain: Communication functioning
Primary endpoint: Mean change from baseline on the frequency of the child's functional utterances on the structured lab observation at 12 Weeks
Endpoint domain: Life impact
Endpoint subdomain: Communication functioning
Primary endpoint: Diagnostic accuracy of dobutamine stress echocardiography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change of Six-minute walking distance (6MWD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of laboratory results of the biomarkers NT-pro BNP/BNP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Health related Quality of Life-EuroQol five dimensions questionnaire (EQ-5D)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Incidence of microbiologically-confirmed VAP (mVAP)
Endpoint domain: Adverse events/effects
Primary endpoint: Effectiveness of fissure sealants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Longevity of fissure sealants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of iPS cells successfully differentiated into RPE cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Quality of Life (QOLIE-10) scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Distress scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Area under the concentration-time curve for 0 to 24 hours (AUC0-24h) of methadone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration at 6 hours (C6h) of methadone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of the chronic transfusion program
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Composite Safety Outcome
Endpoint domain: Adverse events/effects
Primary endpoint: Composite Effectiveness Outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Amount cocaine self-administered
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Direct cocaine effects (cardiovascular)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Effects of DMI on cocaine craving
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Propofol plasma concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change From Peak Viral Load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Efficacy of combined docetaxel & capecitabine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Toxicity of combined docetaxel & capecitabine
Endpoint domain: Adverse events/effects
Primary endpoint: Acoustic Voice Quality Index (AVQI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oral airflow (dm3/s)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glottal leakage (cc/s/dB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intra-oral pressure (hPa)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence rate of symptomatic recurrent P. vivax
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Treatment successful completion
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Adverse Events profile at 90 Day
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Anti-romiplostim or Anti-endogenous Thrombopoietin Neutralizing Antibodies
Endpoint domain: Adverse events/effects
Primary endpoint: Change in fat free body mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in serum albumin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in serum prealbumin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Differentiation of B-ALL Patients in Relapse from Patients in Remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Monitoring of B-ALL Patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fMRI BOLD activation score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of Everolimus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes from Melbourne Assessment 2 (MA-2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes from Pediatric Motor Activity Log-Revised (PMAL-R)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes from ABILHAND-Kids
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Concentration (c max) of TA-65 in serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to reach maximum concentration (T max) of TA-65 in serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Odds ratio for anemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Chest pain measured with VAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Diurnal Intraocular Pressure (IOP) at Week 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrences of red blood cell transfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean Change From Baseline in Best Correct Visual Acuity (BCVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in pulmonary function parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Risk of circulatory system diseases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Risk of endocrine system diseases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Risk of cancers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Protease Activated Receptor-1 Activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Reduction in patient reported pain
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Maximum plasma concentration (Cmax) of 50mg [14C]-SHP626
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration curve (AUC0-t) of 50mg [14C]-SHP626
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total body clearance (CL/F) of 50mg [14C]-SHP626
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical safety parameters
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of hepatitis B virus associated hepatitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Proportion of favourable outcomes
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Left Atrial Effective Refractory Period (LAERP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Migration of prostheses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Achieved weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: biomarkers of breast cancer risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Development of any Major Adverse Cardiovascular Event (MACE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: fMRI brain response during food reward processes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in erythropoietin level in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: decrease in central systolic blood pressure at night
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Participants With Seroresponse to Meningococcal Serogroups A, C, Y, and W
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: percentage of migraine attacks producing pain free response at 2 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minutes With Seizure on EEG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Responders Based on Investigator Evaluation
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of Responders Based on Patient Evaluation
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Daily stool times
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Composite score of changes in general self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Disease Control Rate at 16 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Infectious morbidities
Endpoint domain: Adverse events/effects
Primary endpoint: Inhibitory Control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes